{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T19:32:44Z","timestamp":1783366364990,"version":"3.54.6"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,3,17]],"date-time":"2017-03-17T00:00:00Z","timestamp":1489708800000},"content-version":"am","delay-in-days":350,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Science Foundation of China","doi-asserted-by":"publisher","award":["81371886"],"award-info":[{"award-number":["81371886"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.cca.2016.02.002","type":"journal-article","created":{"date-parts":[[2016,2,3]],"date-time":"2016-02-03T07:47:45Z","timestamp":1454485665000},"page":"102-106","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"special_numbering":"C","title":["Serum human epididymis protein 4 (HE4) may be a better tumor marker in early lung cancer"],"prefix":"10.1016","volume":"455","author":[{"given":"Qian","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiqin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianrang","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2016.02.002_bb0005","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.cca.2016.02.002_bb0010","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/cncr.28509","article-title":"Annual Report to the Nation on the status of cancer, 1975\u20132010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer","volume":"120","author":"Edwards","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.cca.2016.02.002_bb0015","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3322\/caac.20006","article-title":"Cancer statistics, 2009","volume":"59","author":"Jemal","year":"2009","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.cca.2016.02.002_bb0020","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1634\/theoncologist.2007-0153","article-title":"CT screening for lung cancer: update 2007","volume":"13","author":"Henschke","year":"2008","journal-title":"Oncologist"},{"key":"10.1016\/j.cca.2016.02.002_bb0025","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1373\/clinchem.2008.105494","article-title":"National academy of clinical biochemistry laboratory medicine practice guidelines for the use of tumor markers","volume":"54","author":"Diamandis","year":"2008","journal-title":"Clin. Chem."},{"key":"10.1016\/j.cca.2016.02.002_bb0030","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1093\/clinchem\/48.11.1931","article-title":"Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients","volume":"48","author":"Kulpa","year":"2002","journal-title":"Clin. Chem."},{"key":"10.1016\/j.cca.2016.02.002_bb0035","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1373\/clinchem.2010.157073","article-title":"Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases","volume":"57","author":"Escudero","year":"2011","journal-title":"Clin. Chem."},{"key":"10.1016\/j.cca.2016.02.002_bb0040","series-title":"Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology","first-page":"2285","article-title":"HE4 tissue expression and serum HE4 levels in healthy individuals and patients with benign or malignant tumors: a systematic review","volume":"23","author":"Karlsen","year":"2014"},{"key":"10.1016\/j.cca.2016.02.002_bb0045","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0378-1119(99)00035-9","article-title":"Monitoring gene expression profile changes in ovarian carcinomas using cDNA microarray","volume":"229","author":"Wang","year":"1999","journal-title":"Gene"},{"key":"10.1016\/j.cca.2016.02.002_bb0050","first-page":"5895","article-title":"Genetic analysis of early- versus late-stage ovarian tumors","volume":"61","author":"Shridhar","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.cca.2016.02.002_bb0055","first-page":"3695","article-title":"The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma","volume":"63","author":"Hellstrom","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.cca.2016.02.002_bb0060","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s13277-011-0252-8","article-title":"Splice variant HE4-V3 expression is associated with favorable prognosis in pulmonary adenocarcinoma","volume":"33","author":"Tokuishi","year":"2012","journal-title":"Tumour Biol."},{"key":"10.1016\/j.cca.2016.02.002_bb0065","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1515\/cclm-2012-0097","article-title":"Human epididymis protein 4 (HE4) in benign and malignant diseases","volume":"50","author":"Hertlein","year":"2012","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.cca.2016.02.002_bb0070","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/modpathol.3800612","article-title":"Comprehensive analysis of HE4 expression in normal and malignant human tissues","volume":"19","author":"Galgano","year":"2006","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.cca.2016.02.002_bb0075","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.lungcan.2005.01.001","article-title":"Complete resection in lung cancer surgery: proposed definition","volume":"49","author":"Rami-Porta","year":"2005","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cca.2016.02.002_bb0080","series-title":"Cancer Chemotherapy Reports Part 3","first-page":"31","article-title":"Keynote address on biostatistics and data retrieval","volume":"4","author":"Zelen","year":"1973"},{"key":"10.1016\/j.cca.2016.02.002_bb0085","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1465-9921-7-61","article-title":"WFDC2 (HE4): a potential role in the innate immunity of the oral cavity and respiratory tract and the development of adenocarcinomas of the lung","volume":"7","author":"Bingle","year":"2006","journal-title":"Respir. Res."},{"key":"10.1016\/j.cca.2016.02.002_bb0090","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1007\/s13277-012-0499-8","article-title":"Serum level of HE4 is closely associated with pulmonary adenocarcinoma progression","volume":"33","author":"Yamashita","year":"2012","journal-title":"Tumour Biol."},{"key":"10.1016\/j.cca.2016.02.002_bb0095","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s13277-012-0356-9","article-title":"Serum HE4 as a diagnostic and prognostic marker for lung cancer","volume":"33","author":"Iwahori","year":"2012","journal-title":"Tumour Biol."},{"key":"10.1016\/j.cca.2016.02.002_bb0100","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.ejcts.2004.01.029","article-title":"Carcinoembryonic antigen as a predictive factor for postoperative tumor relapse in early-stage lung adenocarcinoma","volume":"25","author":"Sakao","year":"2004","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"10.1016\/j.cca.2016.02.002_bb0105","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.4155\/bio.12.203","article-title":"Clinical significance of CYFRA21-1, Scc-Ag and telomerase activity in serum and pleural effusion of patients with squamous-cell lung cancer","volume":"4","author":"Liu","year":"2012","journal-title":"Bioanalysis"},{"key":"10.1016\/j.cca.2016.02.002_bb0110","first-page":"2136","article-title":"Pro-gastrin-releasing peptide (31-98) is a specific tumor marker in patients with small cell lung carcinoma","volume":"54","author":"Miyake","year":"1994","journal-title":"Cancer Res."},{"key":"10.1016\/j.cca.2016.02.002_bb0115","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s13277-010-0118-5","article-title":"Prognostic significance of HE4 expression in pulmonary adenocarcinoma","volume":"32","author":"Yamashita","year":"2011","journal-title":"Tumour Biol."},{"key":"10.1016\/j.cca.2016.02.002_bb0120","doi-asserted-by":"crossref","first-page":"6847","DOI":"10.1007\/s13277-014-1943-8","article-title":"Evaluating the expression and diagnostic value of human epididymis protein 4 (HE4) in small cell lung cancer","volume":"35","author":"Wang","year":"2014","journal-title":"Tumour Biol."},{"key":"10.1016\/j.cca.2016.02.002_bb0125","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s13277-011-0256-4","article-title":"Human epididymis protein 4 reference limits and natural variation in a Nordic reference population","volume":"33","author":"Bolstad","year":"2012","journal-title":"Tumour Biol."},{"key":"10.1016\/j.cca.2016.02.002_bb0130","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1515\/cclm-2014-0041","article-title":"Serum human epididymis protein 4 (HE4) as a tumor marker in men with lung cancer","volume":"52","author":"Nagy","year":"2014","journal-title":"Clin. Chem. Lab. Med."}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898116300456?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898116300456?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T16:45:39Z","timestamp":1618073139000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898116300456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":26,"alternative-id":["S0009898116300456"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2016.02.002","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum human epididymis protein 4 (HE4) may be a better tumor marker in early lung cancer","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2016.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}